At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 15, 2026 at 07:00 ET
Protara Therapeutics announced positive updated 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-Naïve NMIBC patients, showing a 72.4% complete response rate at any time, 67% at 6 months, and 55% at 12 months, with no Grade 3+ treatment-related adverse events. The company remains on track to initiate the registrational ADVANCED-3 trial in 2H 2026. These data support TARA-002's potential as a differentiated treatment in a large unmet need market.
- 72.4% complete response (CR) rate at any time in BCG-Naïve NMIBC patients (21/29 evaluable).
- 66.7% CR rate at 6 months and 55.0% CR rate at 12 months.
- No Grade 3 or greater treatment-related adverse events; most TRAEs were Grade 1 and transient.
- Registrational ADVANCED-3 trial planned to initiate in 2H 2026 in BCG-Naïve and potentially BCG-Exposed patients.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access